| Literature DB >> 6544815 |
M D Lynn, B Shapiro, J C Sisson, D P Swanson, T J Mangner, D M Wieland, L J Meyers, J V Glowniak, W H Beierwaltes.
Abstract
The radiopharmaceutical m-[131I]iodobenzylguanidine (I-131 MIBG), which is readily taken up by adrenergic vesicles, produces scintigraphic images of pheochromocytomas in man but rarely visualizes normal adrenal glands. Iodine-123 has many potential advantages over I-131 as a radiolabel for MIBG, including shorter half-life, freedom from beta emissions, and increased gamma-camera efficiency. In this study, diagnostic doses of MIBG labeled with I-131 and I-123, with nearly equivalent radiation dosimetry, were compared as imaging agents in eight patients with known or suspected pheochromocytoma. Images of superior quality were obtained with I-123 MIBG, and lesions not visualized using I-131 MIBG were portrayed. In addition, the normal adrenal medullae were visualized on the I-123 MIBG scintigrams in six out of eight patients.Entities:
Mesh:
Substances:
Year: 1984 PMID: 6544815
Source DB: PubMed Journal: J Nucl Med ISSN: 0161-5505 Impact factor: 10.057